Developing companies within Life Science

Facts as of March 31, 2021
NET SALES
9,8 %
EBIT
january-march n/a Msek
ACQUISITION
TIME
2012
BURE'S OWNERSHIP STAKE
9,8 %
REPRESENTATION
FROM BURE
Henrik Blomquist (Member of the board)
NET ASSET VALUE
303 Msek
SHARE OF BURE'S NET ASSET VALUE
1,7 %

MedCap acquires and develops profitable, market-leading niche companies in the life science industry in Northern Europe, with the potential to grow internationally. Operations are conducted in two areas: MedTech and Speciality Pharma.

MedCap is an active and long-term owner with independent subsidiaries that are operated under their respective company names but where overall strategies and synergies are maintained. Companies that have become part of the Group gain access to resources that are difficult to create in smaller companies, networks and active support where this strengthens the business. Governance is primarily exercised through the boards of directors of the owned companies, based on a clear division of mandates, values and company philosophy to create the best possible conditions for profitability and growth.